�ݺ�ߣshows by User: CandySmellie

�ݺ�ߣshows by User: CandySmellie / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: CandySmellie / Fri, 07 Aug 2015 08:47:57 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: CandySmellie Blueprints to blue sky – analyzing the challenges and solutions for IHC companion diagnostics /slideshow/blueprints-to-blue-sky-analyzing-the-challenges-and-solutions-for-ihc-companion-diagnostics/51377986 blueprintstoblueskyanalyzingthechallengesandsolutionsforihccompaniondiagnostics-150807084757-lva1-app6891
Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment. In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability. In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing. By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services. It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations. In clinical multi-center trials it will be easier to standardize and monitor data from each center. And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers. ]]>
Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment. In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability. In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing. By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services. It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations. In clinical multi-center trials it will be easier to standardize and monitor data from each center. And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers. ]]> Fri, 07 Aug 2015 08:47:57 GMT /slideshow/blueprints-to-blue-sky-analyzing-the-challenges-and-solutions-for-ihc-companion-diagnostics/51377986 CandySmellie@slideshare.net(CandySmellie) Blueprints to blue sky – analyzing the challenges and solutions for IHC companion diagnostics CandySmellie Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment. In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability. In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing. By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services. It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations. In clinical multi-center trials it will be easier to standardize and monitor data from each center. And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/blueprintstoblueskyanalyzingthechallengesandsolutionsforihccompaniondiagnostics-150807084757-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment. In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability. In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing. By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services. It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations. In clinical multi-center trials it will be easier to standardize and monitor data from each center. And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers.

Blueprints to blue sky – analyzing the challenges and solutions for IHC companion diagnostics from Candy Smellie

]]> 4624 13 https://cdn.slidesharecdn.com/ss_thumbnails/blueprintstoblueskyanalyzingthechallengesandsolutionsforihccompaniondiagnostics-150807084757-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Understanding and controlling for sample and platform biases in NGS assays /slideshow/understanding-and-controlling-for-sample-and-platform-biases-in-ngs-assays/50837698 understandingandcontrollingforsampleandplatformbiasesinngsassaysfinal-150723091617-lva1-app6892
What is the impact of assay failure in your laboratory and how do you monitor for it? The advancement of next-generation sequencing has provided invaluable resources to researchers in multiple industries and disciplines, and will be a major driver during the personalized medicine revolution that is upon us. However, while the cost of generating sequencing data continues to decrease this does not take into account the significant costs associated with the infrastructure and expertise that are required to develop a robust, routine NGS pipeline. Specifically, as predicted by Sboner, et al in 2011, the cost of the sequencing portion of the experiment continues to decrease and the costs associated with upfront experimental design and downstream analysis dominate the cost of each assay. This is true whether you are performing a pre-clinical R&D project, and perhaps even more so for clinical assays. In the paper, the authors note the unpredictable and considerable ‘human time’ spent on the upstream design and downstream analysis. Here at Horizon, we aim to develop tools that help researchers and clinicians optimize these workflows to make NGS more reliable and ultimately, more affordable by streamlining these resource intensive areas.]]>
What is the impact of assay failure in your laboratory and how do you monitor for it? The advancement of next-generation sequencing has provided invaluable resources to researchers in multiple industries and disciplines, and will be a major driver during the personalized medicine revolution that is upon us. However, while the cost of generating sequencing data continues to decrease this does not take into account the significant costs associated with the infrastructure and expertise that are required to develop a robust, routine NGS pipeline. Specifically, as predicted by Sboner, et al in 2011, the cost of the sequencing portion of the experiment continues to decrease and the costs associated with upfront experimental design and downstream analysis dominate the cost of each assay. This is true whether you are performing a pre-clinical R&D project, and perhaps even more so for clinical assays. In the paper, the authors note the unpredictable and considerable ‘human time’ spent on the upstream design and downstream analysis. Here at Horizon, we aim to develop tools that help researchers and clinicians optimize these workflows to make NGS more reliable and ultimately, more affordable by streamlining these resource intensive areas.]]> Thu, 23 Jul 2015 09:16:17 GMT /slideshow/understanding-and-controlling-for-sample-and-platform-biases-in-ngs-assays/50837698 CandySmellie@slideshare.net(CandySmellie) Understanding and controlling for sample and platform biases in NGS assays CandySmellie What is the impact of assay failure in your laboratory and how do you monitor for it? The advancement of next-generation sequencing has provided invaluable resources to researchers in multiple industries and disciplines, and will be a major driver during the personalized medicine revolution that is upon us. However, while the cost of generating sequencing data continues to decrease this does not take into account the significant costs associated with the infrastructure and expertise that are required to develop a robust, routine NGS pipeline. Specifically, as predicted by Sboner, et al in 2011, the cost of the sequencing portion of the experiment continues to decrease and the costs associated with upfront experimental design and downstream analysis dominate the cost of each assay. This is true whether you are performing a pre-clinical R&D project, and perhaps even more so for clinical assays. In the paper, the authors note the unpredictable and considerable ‘human time’ spent on the upstream design and downstream analysis. Here at Horizon, we aim to develop tools that help researchers and clinicians optimize these workflows to make NGS more reliable and ultimately, more affordable by streamlining these resource intensive areas. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/understandingandcontrollingforsampleandplatformbiasesinngsassaysfinal-150723091617-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is the impact of assay failure in your laboratory and how do you monitor for it? The advancement of next-generation sequencing has provided invaluable resources to researchers in multiple industries and disciplines, and will be a major driver during the personalized medicine revolution that is upon us. However, while the cost of generating sequencing data continues to decrease this does not take into account the significant costs associated with the infrastructure and expertise that are required to develop a robust, routine NGS pipeline. Specifically, as predicted by Sboner, et al in 2011, the cost of the sequencing portion of the experiment continues to decrease and the costs associated with upfront experimental design and downstream analysis dominate the cost of each assay. This is true whether you are performing a pre-clinical R&D project, and perhaps even more so for clinical assays. In the paper, the authors note the unpredictable and considerable ‘human time’ spent on the upstream design and downstream analysis. Here at Horizon, we aim to develop tools that help researchers and clinicians optimize these workflows to make NGS more reliable and ultimately, more affordable by streamlining these resource intensive areas.

Understanding and controlling for sample and platform biases in NGS assays from Candy Smellie

]]> 2186 5 https://cdn.slidesharecdn.com/ss_thumbnails/understandingandcontrollingforsampleandplatformbiasesinngsassaysfinal-150723091617-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Resolving Ambiguity in Target ID Screens - CRISPR-Cas9 Based Essentiality Profiling /slideshow/resolving-ambiguity-in-target-id-screens-crisprcas9-based-essentiality-profiling/50342087 targetessentialitywebinarjuly2015mc-150709104057-lva1-app6892
Pathfinder Target Essentiality Assay Service A new CRISPR─Cas9 based medium throughput assay service for validation of target gene essentiality Can be used to resolve ambiguous screening results Can also provide information on drug target suitability This assay developed at Horizon will enable you to identify genes essential for the growth of specific cancer cell lines. It can be used to definitively resolve ambiguous screening results. Or to provide information on target suitability – by testing essentiality in “normal” cells, or in cancer subtypes different to the proposed patient population]]>
Pathfinder Target Essentiality Assay Service A new CRISPR─Cas9 based medium throughput assay service for validation of target gene essentiality Can be used to resolve ambiguous screening results Can also provide information on drug target suitability This assay developed at Horizon will enable you to identify genes essential for the growth of specific cancer cell lines. It can be used to definitively resolve ambiguous screening results. Or to provide information on target suitability – by testing essentiality in “normal” cells, or in cancer subtypes different to the proposed patient population]]> Thu, 09 Jul 2015 10:40:57 GMT /slideshow/resolving-ambiguity-in-target-id-screens-crisprcas9-based-essentiality-profiling/50342087 CandySmellie@slideshare.net(CandySmellie) Resolving Ambiguity in Target ID Screens - CRISPR-Cas9 Based Essentiality Profiling CandySmellie Pathfinder Target Essentiality Assay Service A new CRISPR─Cas9 based medium throughput assay service for validation of target gene essentiality Can be used to resolve ambiguous screening results Can also provide information on drug target suitability This assay developed at Horizon will enable you to identify genes essential for the growth of specific cancer cell lines. It can be used to definitively resolve ambiguous screening results. Or to provide information on target suitability – by testing essentiality in “normal” cells, or in cancer subtypes different to the proposed patient population <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/targetessentialitywebinarjuly2015mc-150709104057-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> Pathfinder Target Essentiality Assay Service A new CRISPR─Cas9 based medium throughput assay service for validation of target gene essentiality Can be used to resolve ambiguous screening results Can also provide information on drug target suitability This assay developed at Horizon will enable you to identify genes essential for the growth of specific cancer cell lines. It can be used to definitively resolve ambiguous screening results. Or to provide information on target suitability – by testing essentiality in “normal” cells, or in cancer subtypes different to the proposed patient population

Resolving Ambiguity in Target ID Screens - CRISPR-Cas9 Based Essentiality Profiling from Candy Smellie

]]> 1698 10 https://cdn.slidesharecdn.com/ss_thumbnails/targetessentialitywebinarjuly2015mc-150709104057-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Molecular QC: Interpreting your Bioinformatics Pipeline /slideshow/molecular-qc-interpreting-your-bioinformatics-pipeline-49952272/49952272 webinarslides-interpretingyourbioinformaticspipeline-150629104121-lva1-app6892
What is the impact of assay failure in your laboratory and how do you monitor for it? The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all! FFPE artifacts increase with storage time Artifacts go against the statistical power of your variant calling analysis Molecular reference standards help filter out bad mappings and spurious variants Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis NIST and its collaborators shared datasets created with most NGS technologies Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio ~35K variants are predicted having high or moderate impact within the Trio GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother Routinely monitor the performance of your workflows and assays with independent external controls]]>
What is the impact of assay failure in your laboratory and how do you monitor for it? The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all! FFPE artifacts increase with storage time Artifacts go against the statistical power of your variant calling analysis Molecular reference standards help filter out bad mappings and spurious variants Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis NIST and its collaborators shared datasets created with most NGS technologies Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio ~35K variants are predicted having high or moderate impact within the Trio GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother Routinely monitor the performance of your workflows and assays with independent external controls]]> Mon, 29 Jun 2015 10:41:21 GMT /slideshow/molecular-qc-interpreting-your-bioinformatics-pipeline-49952272/49952272 CandySmellie@slideshare.net(CandySmellie) Molecular QC: Interpreting your Bioinformatics Pipeline CandySmellie What is the impact of assay failure in your laboratory and how do you monitor for it? The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all! FFPE artifacts increase with storage time Artifacts go against the statistical power of your variant calling analysis Molecular reference standards help filter out bad mappings and spurious variants Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis NIST and its collaborators shared datasets created with most NGS technologies Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio ~35K variants are predicted having high or moderate impact within the Trio GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother Routinely monitor the performance of your workflows and assays with independent external controls <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/webinarslides-interpretingyourbioinformaticspipeline-150629104121-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is the impact of assay failure in your laboratory and how do you monitor for it? The most heavily degraded samples are not suitable for standard exome coverage: sometimes it’s not even a matter of getting bad sequencing, you might get nothing at all! FFPE artifacts increase with storage time Artifacts go against the statistical power of your variant calling analysis Molecular reference standards help filter out bad mappings and spurious variants Bioinformatics pipelines allow adding Molecular Reference Standards in your joint variant calling pipeline Genome In A Bottle Reference Standards are invaluable for validating variant calling analysis NIST and its collaborators shared datasets created with most NGS technologies Horizon Diagnostics shared annotated, merged variant calls from NIST for the Ashkenazim Trio ~35K variants are predicted having high or moderate impact within the Trio GM24385 (Ashkenazim Son) includes 352 small variants with high/moderate impact which are absent in Father and Mother Routinely monitor the performance of your workflows and assays with independent external controls

Molecular QC: Interpreting your Bioinformatics Pipeline from Candy Smellie

]]> 4139 3 https://cdn.slidesharecdn.com/ss_thumbnails/webinarslides-interpretingyourbioinformaticspipeline-150629104121-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Identification and Prioritization of Drug Combinations for Treatment of Cancer /slideshow/identification-and-prioritization-of-drug-combinations-for-treatment-of-cancer/49258975 webinarjune2015finalversion-150611090631-lva1-app6891
Why are combination drugs important for treatment of cancer? Overview of cHTS screening strategy Example of cHTS screening results Amgen MDM2 inhibitor combination activities Combination drug leads- prioritization Ex vivo assays Tumor microenvironment assays Xenografts cHTS to identify synergies and antagonism Immuno-oncology]]>
Why are combination drugs important for treatment of cancer? Overview of cHTS screening strategy Example of cHTS screening results Amgen MDM2 inhibitor combination activities Combination drug leads- prioritization Ex vivo assays Tumor microenvironment assays Xenografts cHTS to identify synergies and antagonism Immuno-oncology]]> Thu, 11 Jun 2015 09:06:30 GMT /slideshow/identification-and-prioritization-of-drug-combinations-for-treatment-of-cancer/49258975 CandySmellie@slideshare.net(CandySmellie) Identification and Prioritization of Drug Combinations for Treatment of Cancer CandySmellie Why are combination drugs important for treatment of cancer? Overview of cHTS screening strategy Example of cHTS screening results Amgen MDM2 inhibitor combination activities Combination drug leads- prioritization Ex vivo assays Tumor microenvironment assays Xenografts cHTS to identify synergies and antagonism Immuno-oncology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/webinarjune2015finalversion-150611090631-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> Why are combination drugs important for treatment of cancer? Overview of cHTS screening strategy Example of cHTS screening results Amgen MDM2 inhibitor combination activities Combination drug leads- prioritization Ex vivo assays Tumor microenvironment assays Xenografts cHTS to identify synergies and antagonism Immuno-oncology

Identification and Prioritization of Drug Combinations for Treatment of Cancer from Candy Smellie

]]> 1859 6 https://cdn.slidesharecdn.com/ss_thumbnails/webinarjune2015finalversion-150611090631-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Molecular QC: Using Reference Standards in NGS Pipelines /slideshow/final-2-molecular-qc-using-reference-standards-in-ngs-pipelines-nl-final/48598016 final2-molecularqc-usingreferencestandardsinngspipelines-nlfinal-150526083236-lva1-app6891
Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run. By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications. Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.]]>
Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run. By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications. Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.]]> Tue, 26 May 2015 08:32:36 GMT /slideshow/final-2-molecular-qc-using-reference-standards-in-ngs-pipelines-nl-final/48598016 CandySmellie@slideshare.net(CandySmellie) Molecular QC: Using Reference Standards in NGS Pipelines CandySmellie Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run. By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications. Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/final2-molecularqc-usingreferencestandardsinngspipelines-nlfinal-150526083236-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds" /> Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run. By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications. Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.

Molecular QC: Using Reference Standards in NGS Pipelines from Candy Smellie

]]> 3220 5 https://cdn.slidesharecdn.com/ss_thumbnails/final2-molecularqc-usingreferencestandardsinngspipelines-nlfinal-150526083236-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Improving Immunohistochemistry Standardization in your Laboratory: Renewable Reproducible and Consistent Reference Standards /slideshow/15-57-ihc-webinar/47858868 15-5-7ihcwebinar-150507104636-lva1-app6892
What is the impact of assay failure in your laboratory and how do you monitor for it? To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.]]>
What is the impact of assay failure in your laboratory and how do you monitor for it? To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.]]> Thu, 07 May 2015 10:46:36 GMT /slideshow/15-57-ihc-webinar/47858868 CandySmellie@slideshare.net(CandySmellie) Improving Immunohistochemistry Standardization in your Laboratory: Renewable Reproducible and Consistent Reference Standards CandySmellie What is the impact of assay failure in your laboratory and how do you monitor for it? To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/15-5-7ihcwebinar-150507104636-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is the impact of assay failure in your laboratory and how do you monitor for it? To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.

Improving Immunohistochemistry Standardization in your Laboratory: Renewable Reproducible and Consistent Reference Standards from Candy Smellie

]]> 1999 6 https://cdn.slidesharecdn.com/ss_thumbnails/15-5-7ihcwebinar-150507104636-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cell Free DNA comes to the Clinic /slideshow/cell-free-dna-comes-to-the-clinic/47277891 cfdnappt-150422034106-conversion-gate02
Overall, testing cfDNA has four distinct advantages over conventional biopsies, being: Cost-effective approach; Simplified sample collection procedures; Reduced impact to the patient and; Easily analyzed.]]>
Overall, testing cfDNA has four distinct advantages over conventional biopsies, being: Cost-effective approach; Simplified sample collection procedures; Reduced impact to the patient and; Easily analyzed.]]> Wed, 22 Apr 2015 03:41:06 GMT /slideshow/cell-free-dna-comes-to-the-clinic/47277891 CandySmellie@slideshare.net(CandySmellie) Cell Free DNA comes to the Clinic CandySmellie Overall, testing cfDNA has four distinct advantages over conventional biopsies, being: Cost-effective approach; Simplified sample collection procedures; Reduced impact to the patient and; Easily analyzed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cfdnappt-150422034106-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> Overall, testing cfDNA has four distinct advantages over conventional biopsies, being: Cost-effective approach; Simplified sample collection procedures; Reduced impact to the patient and; Easily analyzed.

Cell Free DNA comes to the Clinic from Candy Smellie

]]> 3048 4 https://cdn.slidesharecdn.com/ss_thumbnails/cfdnappt-150422034106-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular cell biology /slideshow/genome-editing-comes-of-age-45790804/45790804 2015genomeeditingcomesofagecgs-150313044621-conversion-gate01
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’ In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients. Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models. AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs) It is in effect a highly effective DNA delivery mechanism After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.]]>
Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’ In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients. Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models. AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs) It is in effect a highly effective DNA delivery mechanism After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.]]> Fri, 13 Mar 2015 04:46:20 GMT /slideshow/genome-editing-comes-of-age-45790804/45790804 CandySmellie@slideshare.net(CandySmellie) Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular cell biology CandySmellie Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’ In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients. Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models. AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs) It is in effect a highly effective DNA delivery mechanism After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2015genomeeditingcomesofagecgs-150313044621-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Information is no longer a bottleneck, emphasis is shifting to the ‘what does it all mean’ In a translational context we hope that by answering that question we will be able to is to characterise the genetics that drive disease, and indeed develop drugs and diagnostics that are personalised to patients. Genome editing provides the link between the information here, and this outcome here, by allowing scientists to recapitulate specific genetic alterations in any gene in any living tissue to probe function, develop disease models and identify therapeutic strategies. So, not only do we now have unparalleled access to genetic information, but we now have the tools to most accuartely understand what this genetic information – with genome editing allowing us to explore the genetic drivers of disease in physiological models. AAV is a single-stranded, linear DNA virus with a a 4.7 kb genome which for the purpose of genome editing is replaced almost in entirety with the targeting vector sequence (except for the iTRs) It is in effect a highly effective DNA delivery mechanism After entry of the vector into the cell, target-specific homologous DNA is believed to activate and recruit HR-dependent repair factors can induce HR at rates approximately 1,000 times greater than plasmid based double stranded DNA vectors, but the mechanism by which it achieves this is still largely unknown By including a selection cassette can select for cells that have integrated the targeting vector, and then screen for clones which have undergone targeted insetion rather than random integration, which will generally be around 1%.

Genome Editing Comes of Age; CRISPR, rAAV and the new landscape of molecular cell biology from Candy Smellie

]]> 3185 7 https://cdn.slidesharecdn.com/ss_thumbnails/2015genomeeditingcomesofagecgs-150313044621-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Addressing the Pre-PCR Analytical �Variability of FFPE Samples /slideshow/addressing-the-prepcr-analytical-variability-of-ffpe-samples/45466631 15225addressingthepre-pcranalyticalvariabilityofffpesamplesfinal-mc-150305055757-conversion-gate01
Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance. In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved.]]>
Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance. In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved.]]> Thu, 05 Mar 2015 05:57:55 GMT /slideshow/addressing-the-prepcr-analytical-variability-of-ffpe-samples/45466631 CandySmellie@slideshare.net(CandySmellie) Addressing the Pre-PCR Analytical �Variability of FFPE Samples CandySmellie Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance. In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/15225addressingthepre-pcranalyticalvariabilityofffpesamplesfinal-mc-150305055757-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance. In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved.

Addressing the Pre-PCR Analytical Variability of FFPE Samples from Candy Smellie

]]> 1416 3 https://cdn.slidesharecdn.com/ss_thumbnails/15225addressingthepre-pcranalyticalvariabilityofffpesamplesfinal-mc-150305055757-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Using reference materials to meet validation & verification requirements for clinical laboratory procedures /slideshow/using-reference-materials-to-meet-validation-and-verification-requirements-for-clinical-laboratory-procedures-including-ld-ts/44489372 1524usingreferencematerialstomeetvalidationandverificationrequirementsforclinicallaboratoryprocedure-150210043623-conversion-gate01
Bio-Specimens used in Molecular Diagnostics Most clinical tissue samples are preserved in FFPE FFPE samples are now being used for molecular diagnostic testing FFPE based studies: every specimen is different in terms of % tumor contribution to the specimen and % mutation contribution to the tumor External Quality Assessment Proficiency Testing Scheme Therapeutic choices are made based upon these results False positive and false negative results are detrimental to the patient Validation occurs across multiple areas of the clinical laboratory. Validation can include equipment, reagents, operators, platforms. Two of the key areas are test and platform validation. Test development includes: Establishing protocol Optimising performance Determining pooling parameters Using synthetic variants to compare tools and facilitate optimisation Test validation includes: Determine parameters First tests developed carry highest validation requirements Changes to tests must follow re-validation required against existing test Platform validation Cumulative performance data established Determine confidence intervals Track and validate software versions Changes to platform must follow re-validation required against existing platform]]>
Bio-Specimens used in Molecular Diagnostics Most clinical tissue samples are preserved in FFPE FFPE samples are now being used for molecular diagnostic testing FFPE based studies: every specimen is different in terms of % tumor contribution to the specimen and % mutation contribution to the tumor External Quality Assessment Proficiency Testing Scheme Therapeutic choices are made based upon these results False positive and false negative results are detrimental to the patient Validation occurs across multiple areas of the clinical laboratory. Validation can include equipment, reagents, operators, platforms. Two of the key areas are test and platform validation. Test development includes: Establishing protocol Optimising performance Determining pooling parameters Using synthetic variants to compare tools and facilitate optimisation Test validation includes: Determine parameters First tests developed carry highest validation requirements Changes to tests must follow re-validation required against existing test Platform validation Cumulative performance data established Determine confidence intervals Track and validate software versions Changes to platform must follow re-validation required against existing platform]]> Tue, 10 Feb 2015 04:36:23 GMT /slideshow/using-reference-materials-to-meet-validation-and-verification-requirements-for-clinical-laboratory-procedures-including-ld-ts/44489372 CandySmellie@slideshare.net(CandySmellie) Using reference materials to meet validation & verification requirements for clinical laboratory procedures CandySmellie Bio-Specimens used in Molecular Diagnostics Most clinical tissue samples are preserved in FFPE FFPE samples are now being used for molecular diagnostic testing FFPE based studies: every specimen is different in terms of % tumor contribution to the specimen and % mutation contribution to the tumor External Quality Assessment Proficiency Testing Scheme Therapeutic choices are made based upon these results False positive and false negative results are detrimental to the patient Validation occurs across multiple areas of the clinical laboratory. Validation can include equipment, reagents, operators, platforms. Two of the key areas are test and platform validation. Test development includes: Establishing protocol Optimising performance Determining pooling parameters Using synthetic variants to compare tools and facilitate optimisation Test validation includes: Determine parameters First tests developed carry highest validation requirements Changes to tests must follow re-validation required against existing test Platform validation Cumulative performance data established Determine confidence intervals Track and validate software versions Changes to platform must follow re-validation required against existing platform <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/1524usingreferencematerialstomeetvalidationandverificationrequirementsforclinicallaboratoryprocedure-150210043623-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Bio-Specimens used in Molecular Diagnostics Most clinical tissue samples are preserved in FFPE FFPE samples are now being used for molecular diagnostic testing FFPE based studies: every specimen is different in terms of % tumor contribution to the specimen and % mutation contribution to the tumor External Quality Assessment Proficiency Testing Scheme Therapeutic choices are made based upon these results False positive and false negative results are detrimental to the patient Validation occurs across multiple areas of the clinical laboratory. Validation can include equipment, reagents, operators, platforms. Two of the key areas are test and platform validation. Test development includes: Establishing protocol Optimising performance Determining pooling parameters Using synthetic variants to compare tools and facilitate optimisation Test validation includes: Determine parameters First tests developed carry highest validation requirements Changes to tests must follow re-validation required against existing test Platform validation Cumulative performance data established Determine confidence intervals Track and validate software versions Changes to platform must follow re-validation required against existing platform

Using reference materials to meet validation & verification requirements for clinical laboratory procedures from Candy Smellie

]]> 1928 5 https://cdn.slidesharecdn.com/ss_thumbnails/1524usingreferencematerialstomeetvalidationandverificationrequirementsforclinicallaboratoryprocedure-150210043623-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Genome Editing Comes of Age /slideshow/2015-genome-editing-comes-of-age2-cgs/44253151 2015genomeeditingcomesofage2cgs-150204042038-conversion-gate02
Gene Targeting Techniques – an overview Genome Editing Tools rAAV CRISPR/Cas9 Key Considerations for Gene Editing Genome Editing at scale High through Knock-out Cell Line Generation Genome Wide sgRNA Synthetic Lethality Screening]]>
Gene Targeting Techniques – an overview Genome Editing Tools rAAV CRISPR/Cas9 Key Considerations for Gene Editing Genome Editing at scale High through Knock-out Cell Line Generation Genome Wide sgRNA Synthetic Lethality Screening]]> Wed, 04 Feb 2015 04:20:38 GMT /slideshow/2015-genome-editing-comes-of-age2-cgs/44253151 CandySmellie@slideshare.net(CandySmellie) Genome Editing Comes of Age CandySmellie Gene Targeting Techniques – an overview Genome Editing Tools rAAV CRISPR/Cas9 Key Considerations for Gene Editing Genome Editing at scale High through Knock-out Cell Line Generation Genome Wide sgRNA Synthetic Lethality Screening <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2015genomeeditingcomesofage2cgs-150204042038-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> Gene Targeting Techniques – an overview Genome Editing Tools rAAV CRISPR/Cas9 Key Considerations for Gene Editing Genome Editing at scale High through Knock-out Cell Line Generation Genome Wide sgRNA Synthetic Lethality Screening

Genome Editing Comes of Age from Candy Smellie

]]> 3678 13 https://cdn.slidesharecdn.com/ss_thumbnails/2015genomeeditingcomesofage2cgs-150204042038-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 CRISPR: Gene editing for everyone /slideshow/crispr-gene-editing-for-everyone/43579245 slidesharecrisprgene-editingforeveryone-150116041009-conversion-gate02
CRISPR/Cas9 gene editing is based on a microbial restriction system, that has been harnessed for genome targeting using only a short sequence of RNA as a guide. The beauty of the system is that unlike protein binding based technologies such as Zinc Fingers and TALENs which require complex protein engineering, the design rules are very simple, and it is this fact that is allowing CRISPR to take genome engineering from a relatively niche persuit to the mainstream scientific community. The principle of the system is that a short guide RNA, homologous to the target site recruits a nuclease – Cas9 This then cuts the dsDNA, triggering repair by either the low fidelity NHEJ pathway, or by HDR in the presence of an exogenous donor sequence. High Efficiencies for both knockouts and knock-ins have been reported and whilst there are understandable concerns about specificity, new methodologies to address these are now being developed The system itself is comprised of three key components the Cas9 protein, which cuts/cleaves the DNA and Two RNAs - a crispr RNA contains the sequence homologous to the target site and a trans-activating crisprRNA (or TracrRNA) which recruits the nuclease/crispr complex For genome editing, the crisperRNA and TraceRNA are generally now constructed together into a single guideRNA or sgRNA Genome editing is elicited through hybridization of the sgRNA with its matching genomic sequence, and the recruitment of the Cas9, which cleaves at the target site.]]>
CRISPR/Cas9 gene editing is based on a microbial restriction system, that has been harnessed for genome targeting using only a short sequence of RNA as a guide. The beauty of the system is that unlike protein binding based technologies such as Zinc Fingers and TALENs which require complex protein engineering, the design rules are very simple, and it is this fact that is allowing CRISPR to take genome engineering from a relatively niche persuit to the mainstream scientific community. The principle of the system is that a short guide RNA, homologous to the target site recruits a nuclease – Cas9 This then cuts the dsDNA, triggering repair by either the low fidelity NHEJ pathway, or by HDR in the presence of an exogenous donor sequence. High Efficiencies for both knockouts and knock-ins have been reported and whilst there are understandable concerns about specificity, new methodologies to address these are now being developed The system itself is comprised of three key components the Cas9 protein, which cuts/cleaves the DNA and Two RNAs - a crispr RNA contains the sequence homologous to the target site and a trans-activating crisprRNA (or TracrRNA) which recruits the nuclease/crispr complex For genome editing, the crisperRNA and TraceRNA are generally now constructed together into a single guideRNA or sgRNA Genome editing is elicited through hybridization of the sgRNA with its matching genomic sequence, and the recruitment of the Cas9, which cleaves at the target site.]]> Fri, 16 Jan 2015 04:10:09 GMT /slideshow/crispr-gene-editing-for-everyone/43579245 CandySmellie@slideshare.net(CandySmellie) CRISPR: Gene editing for everyone CandySmellie CRISPR/Cas9 gene editing is based on a microbial restriction system, that has been harnessed for genome targeting using only a short sequence of RNA as a guide. The beauty of the system is that unlike protein binding based technologies such as Zinc Fingers and TALENs which require complex protein engineering, the design rules are very simple, and it is this fact that is allowing CRISPR to take genome engineering from a relatively niche persuit to the mainstream scientific community. The principle of the system is that a short guide RNA, homologous to the target site recruits a nuclease – Cas9 This then cuts the dsDNA, triggering repair by either the low fidelity NHEJ pathway, or by HDR in the presence of an exogenous donor sequence. High Efficiencies for both knockouts and knock-ins have been reported and whilst there are understandable concerns about specificity, new methodologies to address these are now being developed The system itself is comprised of three key components the Cas9 protein, which cuts/cleaves the DNA and Two RNAs - a crispr RNA contains the sequence homologous to the target site and a trans-activating crisprRNA (or TracrRNA) which recruits the nuclease/crispr complex For genome editing, the crisperRNA and TraceRNA are generally now constructed together into a single guideRNA or sgRNA Genome editing is elicited through hybridization of the sgRNA with its matching genomic sequence, and the recruitment of the Cas9, which cleaves at the target site. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/slidesharecrisprgene-editingforeveryone-150116041009-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> CRISPR/Cas9 gene editing is based on a microbial restriction system, that has been harnessed for genome targeting using only a short sequence of RNA as a guide. The beauty of the system is that unlike protein binding based technologies such as Zinc Fingers and TALENs which require complex protein engineering, the design rules are very simple, and it is this fact that is allowing CRISPR to take genome engineering from a relatively niche persuit to the mainstream scientific community. The principle of the system is that a short guide RNA, homologous to the target site recruits a nuclease – Cas9 This then cuts the dsDNA, triggering repair by either the low fidelity NHEJ pathway, or by HDR in the presence of an exogenous donor sequence. High Efficiencies for both knockouts and knock-ins have been reported and whilst there are understandable concerns about specificity, new methodologies to address these are now being developed The system itself is comprised of three key components the Cas9 protein, which cuts/cleaves the DNA and Two RNAs - a crispr RNA contains the sequence homologous to the target site and a trans-activating crisprRNA (or TracrRNA) which recruits the nuclease/crispr complex For genome editing, the crisperRNA and TraceRNA are generally now constructed together into a single guideRNA or sgRNA Genome editing is elicited through hybridization of the sgRNA with its matching genomic sequence, and the recruitment of the Cas9, which cleaves at the target site.

CRISPR: Gene editing for everyone from Candy Smellie

]]> 2454 5 https://cdn.slidesharecdn.com/ss_thumbnails/slidesharecrisprgene-editingforeveryone-150116041009-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 RNA-based screening in drug discovery – introducing sgRNA technologies /slideshow/rnabased-screening-in-drug-discovery-introducing-sgrna-technologies/43463502 rnascreeningwebinar09dec2014slideshare-150113054006-conversion-gate01
RNA-based screening in drug discovery Use of X-MAN™ isogenic cell lines in RNAi screening approaches Comparison of siRNA and sgRNA screening approaches The challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening Using CRISPR-Cas9 sgRNA for target identification and patient stratification Moving from screening hit to target validation sgRNA screening: not just KOs]]>
RNA-based screening in drug discovery Use of X-MAN™ isogenic cell lines in RNAi screening approaches Comparison of siRNA and sgRNA screening approaches The challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening Using CRISPR-Cas9 sgRNA for target identification and patient stratification Moving from screening hit to target validation sgRNA screening: not just KOs]]> Tue, 13 Jan 2015 05:40:06 GMT /slideshow/rnabased-screening-in-drug-discovery-introducing-sgrna-technologies/43463502 CandySmellie@slideshare.net(CandySmellie) RNA-based screening in drug discovery – introducing sgRNA technologies CandySmellie RNA-based screening in drug discovery Use of X-MAN™ isogenic cell lines in RNAi screening approaches Comparison of siRNA and sgRNA screening approaches The challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening Using CRISPR-Cas9 sgRNA for target identification and patient stratification Moving from screening hit to target validation sgRNA screening: not just KOs <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rnascreeningwebinar09dec2014slideshare-150113054006-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> RNA-based screening in drug discovery Use of X-MAN™ isogenic cell lines in RNAi screening approaches Comparison of siRNA and sgRNA screening approaches The challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening Using CRISPR-Cas9 sgRNA for target identification and patient stratification Moving from screening hit to target validation sgRNA screening: not just KOs

RNA-based screening in drug discovery – introducing sgRNA technologies from Candy Smellie

]]> 2178 8 https://cdn.slidesharecdn.com/ss_thumbnails/rnascreeningwebinar09dec2014slideshare-150113054006-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 To assess the effect of formalin on genomic DNA and assay performance for somatic variant detection /slideshow/11-12-14-formalin-powerpoint-jw/42645006 111214formalinpowerpointjw-141212092243-conversion-gate02
What is the impact of assay failure in your laboratory and how do you monitor for it? Application of Companion Diagnostics - driving better treatment for cancer patients]]>
What is the impact of assay failure in your laboratory and how do you monitor for it? Application of Companion Diagnostics - driving better treatment for cancer patients]]> Fri, 12 Dec 2014 09:22:43 GMT /slideshow/11-12-14-formalin-powerpoint-jw/42645006 CandySmellie@slideshare.net(CandySmellie) To assess the effect of formalin on genomic DNA and assay performance for somatic variant detection CandySmellie What is the impact of assay failure in your laboratory and how do you monitor for it? Application of Companion Diagnostics - driving better treatment for cancer patients <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/111214formalinpowerpointjw-141212092243-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is the impact of assay failure in your laboratory and how do you monitor for it? Application of Companion Diagnostics - driving better treatment for cancer patients

To assess the effect of formalin on genomic DNA and assay performance for somatic variant detection from Candy Smellie

]]> 1449 4 https://cdn.slidesharecdn.com/ss_thumbnails/111214formalinpowerpointjw-141212092243-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Overview of Quality Management System /slideshow/141112-clinical-trials-quality-presentation/41808661 141112clinicaltrialsqualitypresentation-141120090423-conversion-gate01
Improvement projects across the business to reduce waste and improve efficiency Develop and execute first stage of FDA Strategy Considerations to extend ISO 13485 scope to additional product lines]]>
Improvement projects across the business to reduce waste and improve efficiency Develop and execute first stage of FDA Strategy Considerations to extend ISO 13485 scope to additional product lines]]> Thu, 20 Nov 2014 09:04:23 GMT /slideshow/141112-clinical-trials-quality-presentation/41808661 CandySmellie@slideshare.net(CandySmellie) Overview of Quality Management System CandySmellie Improvement projects across the business to reduce waste and improve efficiency Develop and execute first stage of FDA Strategy Considerations to extend ISO 13485 scope to additional product lines <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/141112clinicaltrialsqualitypresentation-141120090423-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Improvement projects across the business to reduce waste and improve efficiency Develop and execute first stage of FDA Strategy Considerations to extend ISO 13485 scope to additional product lines

Overview of Quality Management System from Candy Smellie

]]> 992 6 https://cdn.slidesharecdn.com/ss_thumbnails/141112clinicaltrialsqualitypresentation-141120090423-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines /slideshow/ngs-sheffield-workshop3-introlouisaludbrook/41808565 ngssheffieldworkshop3introlouisaludbrook-141120090232-conversion-gate01
HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines]]>
HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines]]> Thu, 20 Nov 2014 09:02:31 GMT /slideshow/ngs-sheffield-workshop3-introlouisaludbrook/41808565 CandySmellie@slideshare.net(CandySmellie) HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines CandySmellie HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ngssheffieldworkshop3introlouisaludbrook-141120090232-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines

HDx™ Reference Standards and Reference Materials for Next Generation Sequencing somatic variant pipelines from Candy Smellie

]]> 2408 6 https://cdn.slidesharecdn.com/ss_thumbnails/ngssheffieldworkshop3introlouisaludbrook-141120090232-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Translating Genomes | Personalizing Medicine /slideshow/translating-genomes-personalizing-medicine/41808417 cell-basedassayswebinar12nov2014slideshare-141120085946-conversion-gate02
Using cell-based assays in the development of efficacious cancer therapies]]>
Using cell-based assays in the development of efficacious cancer therapies]]> Thu, 20 Nov 2014 08:59:46 GMT /slideshow/translating-genomes-personalizing-medicine/41808417 CandySmellie@slideshare.net(CandySmellie) Translating Genomes | Personalizing Medicine CandySmellie Using cell-based assays in the development of efficacious cancer therapies <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cell-basedassayswebinar12nov2014slideshare-141120085946-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> Using cell-based assays in the development of efficacious cancer therapies

Translating Genomes | Personalizing Medicine from Candy Smellie

]]> 532 4 https://cdn.slidesharecdn.com/ss_thumbnails/cell-basedassayswebinar12nov2014slideshare-141120085946-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Translating Genomes | Personalizing Medicine /slideshow/gene-editing-webinar-21-oct-2014-slideshare/41808283 gene-editingwebinar21oct2014slideshare-141120085659-conversion-gate01
Gene-editing evolved - Combining CRISPR, rAAV and ZFNs for maximum versatility and minimal hassle]]>
Gene-editing evolved - Combining CRISPR, rAAV and ZFNs for maximum versatility and minimal hassle]]> Thu, 20 Nov 2014 08:56:59 GMT /slideshow/gene-editing-webinar-21-oct-2014-slideshare/41808283 CandySmellie@slideshare.net(CandySmellie) Translating Genomes | Personalizing Medicine CandySmellie Gene-editing evolved - Combining CRISPR, rAAV and ZFNs for maximum versatility and minimal hassle <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/gene-editingwebinar21oct2014slideshare-141120085659-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Gene-editing evolved - Combining CRISPR, rAAV and ZFNs for maximum versatility and minimal hassle

Translating Genomes | Personalizing Medicine from Candy Smellie

]]> 1123 6 https://cdn.slidesharecdn.com/ss_thumbnails/gene-editingwebinar21oct2014slideshare-141120085659-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 The clinical application development and validation of cell free dna assays -platforms - horizon diagnostics /slideshow/the-clinical-application-development-and-validation-of-cell-free-dna-assays-platforms-horizon-diagnostics/40758545 theclinicalapplicationdevelopmentandvalidationofcell-freednaassays-platforms-horizondiagnostics-141027043952-conversion-gate01
What is the impact of assay failure in your laboratory and how do you monitor for it? In cancer patients, cell-free DNA carries tumour-related genetic alterations that are relevant to cancer development, disease progression and response to therapy. Cell-free DNA detection allows: Early detection Frequent sampling Monitoring of disease progression Measure response to therapy Detection of resistance mutation Non-invasive diagnostic tool development]]>
What is the impact of assay failure in your laboratory and how do you monitor for it? In cancer patients, cell-free DNA carries tumour-related genetic alterations that are relevant to cancer development, disease progression and response to therapy. Cell-free DNA detection allows: Early detection Frequent sampling Monitoring of disease progression Measure response to therapy Detection of resistance mutation Non-invasive diagnostic tool development]]> Mon, 27 Oct 2014 04:39:52 GMT /slideshow/the-clinical-application-development-and-validation-of-cell-free-dna-assays-platforms-horizon-diagnostics/40758545 CandySmellie@slideshare.net(CandySmellie) The clinical application development and validation of cell free dna assays -platforms - horizon diagnostics CandySmellie What is the impact of assay failure in your laboratory and how do you monitor for it? In cancer patients, cell-free DNA carries tumour-related genetic alterations that are relevant to cancer development, disease progression and response to therapy. Cell-free DNA detection allows: Early detection Frequent sampling Monitoring of disease progression Measure response to therapy Detection of resistance mutation Non-invasive diagnostic tool development <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/theclinicalapplicationdevelopmentandvalidationofcell-freednaassays-platforms-horizondiagnostics-141027043952-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is the impact of assay failure in your laboratory and how do you monitor for it? In cancer patients, cell-free DNA carries tumour-related genetic alterations that are relevant to cancer development, disease progression and response to therapy. Cell-free DNA detection allows: Early detection Frequent sampling Monitoring of disease progression Measure response to therapy Detection of resistance mutation Non-invasive diagnostic tool development

The clinical application development and validation of cell free dna assays -platforms - horizon diagnostics from Candy Smellie

]]> 2058 5 https://cdn.slidesharecdn.com/ss_thumbnails/theclinicalapplicationdevelopmentandvalidationofcell-freednaassays-platforms-horizondiagnostics-141027043952-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-CandySmellie-48x48.jpg?cb=1592308462 Effective, versatile and committed marketing co-ordinator with particular expertise in customer communication at all levels. Skills include: planning and organisation, project management, problem solving and influencing. Excellent team player who loves designing, implementing and reporting on campaigns and with a passion for promoting the company through the various social media platforms. www-smartinfrastructure.eng.cam.ac.uk/ https://cdn.slidesharecdn.com/ss_thumbnails/blueprintstoblueskyanalyzingthechallengesandsolutionsforihccompaniondiagnostics-150807084757-lva1-app6891-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/blueprints-to-blue-sky-analyzing-the-challenges-and-solutions-for-ihc-companion-diagnostics/51377986 Blueprints to blue sky... https://cdn.slidesharecdn.com/ss_thumbnails/understandingandcontrollingforsampleandplatformbiasesinngsassaysfinal-150723091617-lva1-app6892-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/understanding-and-controlling-for-sample-and-platform-biases-in-ngs-assays/50837698 Understanding and cont... https://cdn.slidesharecdn.com/ss_thumbnails/targetessentialitywebinarjuly2015mc-150709104057-lva1-app6892-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/resolving-ambiguity-in-target-id-screens-crisprcas9-based-essentiality-profiling/50342087 Resolving Ambiguity in...